DifGen Pharmaceuticals LLC Announces U.S. FDA Approval of Epinephrine Injection USP, 1 mg/mL, Single-Dose Vials
DifGen Pharmaceuticals LLC Announces U.S. FDA Approval of Epinephrine Injection USP, 1 mg/mL, Single-Dose Vials
DifGen Pharmaceuticals
Private
DifGen Pharmaceuticals is a specialty pharma company. See today's news for the latest developments.
Company Info
Sector:Specialty Pharma
Headquarters:Somerset, New Jersey, USA
Founded:2006
Website:www.difgenpharma.com/
Upcoming Milestones & Key Dates
2026-07-28
Milestone
Initial profile created
Clinical Development Pipeline
See pipeline
Target: See pipelineRecent News
Aveva Drug Delivery Systems prevails on appeal, Federal Circuit affirms non-infringement of ZTlido patents
The Federal Circuit affirmed a district court ruling that Aveva Drug Delivery Systems' generic ZTlido product does not infringe Scilex's patents, preparing the company for an imminent launch of its generic product with 180-day exclusivity.
DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101
DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101.
Leadership Team
See company website
Leadership team